PTC Therapeutics Announces FDA Approval of AADC Deficiency ...
1 day ago · News provided by PTC Therapeutics, Inc. Nov 13, 2024, 18:02 ET. Share this article. Share to X. Share this article. Share to X - First-ever FDA approval for gene therapy directly administered to ...
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights ...
6 days ago · PTC Therapeutics Inc (NASDAQ:PTCT) achieved total revenue of $197 million in the third quarter, with $124 million from the DMD franchise. The company closed the quarter with over $1 billion in ...
Newsroom | The Latest on PTC Therapeutics
Read the latest updates on innovations, research, rare disease treatments, business & finance, and community relations at PTC Therapeutics.
Press Releases - PTC Therapeutics, Inc.
WARREN, N.J. , Oct. 1, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of sepiapterin for the treatment of pediatric and adult patients living with phenylketonuria (PKU).
PTC Therapeutics Announces FDA Acceptance and Priority …
2 days ago · WARREN, N.J., May 14, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a …
PTC Therapeutics Announces Positive Results from Long-Term ...
Oct 8, 2024 · PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program. - Statistically significant results on primary endpoint of long-term study analyses -. - Following FDA pre-NDA feedback, submission on track for December 2024 -.
PTC Therapeutics Announces FDA Target Regulatory Action Date ...
WARREN, N.J., Oct. 14, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has set a target regulatory action date of July 29, 2025, for the review of the New...
PTC Therapeutics Announces FDA Acceptance and Priority …
May 14, 2024 · PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the...
PTC Therapeutics Provides an Update on Commercial Progress ...
Jan 8, 2024 · PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 42nd Annual J.P. Morgan Healthcare Conference today, Monday, January 8, at...
PTC gets another chance to keep Translarna's EU authorization
May 20, 2024 · Four months after Europe's drug reviewers doubled down and recommended the withdrawal of PTC Therapeutics' Translarna for lack of efficacy, the drug's regulatory odyssey is taking yet another...